Advertisement

Breast Cancer Research and Treatment

, Volume 171, Issue 1, pp 235–242 | Cite as

Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer

  • Christine Y. Lu
  • Fang Zhang
  • Anita K. Wagner
  • Larissa Nekhlyudov
  • Craig C. Earle
  • Matthew Callahan
  • Robert LeCates
  • Xin Xu
  • Dennis Ross-Degnan
  • J. Frank Wharam
Brief Report

Abstract

Objective

High-deductible health plans (HDHPs) have become the predominant commercial health insurance arrangement in the US. HDHPs require substantial out-of-pocket (OOP) costs for most services but often exempt medications from high cost sharing. We examined effects of HDHPs on OOP costs and utilization of adjuvant hormonal therapy (AHT), which are fundamental care for patients with breast cancer.

Methods

This controlled quasi-experimental study used claims data (2003–2012) from a large national health insurer. We included 986 women with incident early-stage breast cancer, age 25–64 years, insured by employers that mandated a transition from low-deductible (≤ $500/year) to high-deductible (≥ $1000/year) coverage, and 3479 propensity score-matched controls whose employers offered only low-deductible plans. We examined AHT utilization and OOP costs per person-year before and after the HDHP switch.

Results

At baseline, the OOP costs for AHT were $40.41 and $36.55 per person-year among the HDHP and control groups. After the HDHP switch, the OOP costs for AHT were $91.76 and $72.98 per person-year among the HDHP and control groups, respectively. AHT OOP costs increased among HDHP members relative to controls but the change was not significant (relative change 13.72% [95% CI − 9.25, 36.70%]). AHT use among HDHP members did not change compared to controls (relative change of 2.73% [95% CI − 14.01, 19.48%]); the change in aromatase inhibitor use was − 11.94% (95% CI − 32.76, 8.88%) and the change in tamoxifen use was 20.65% (95% CI − 8.01, 49.32%).

Conclusion

We did not detect significant changes in AHT use after the HDHP switch. Findings might be related to modest increases in overall AHT OOP costs, the availability of low-cost generic tamoxifen, and patient awareness that AHT can prolong life and health. Minimizing OOP cost increases for essential medications might represent a feasible approach for maintaining medication adherence among HDHP members with incident breast cancer.

Keywords

Breast cancer care High-deductible health insurance Adjuvant hormonal therapy Tamoxifen Aromatase inhibitors 

Notes

Acknowledgements

This work was supported by a Grant from the National Cancer Institute and the National Institute of Health Office of the Director under Grant No. R01CA172639 (PI: Wharam). The Research Protocol was approved by the Harvard Pilgrim Health Care Institutional Review Board. Dr. Zhang and Mr. Xu primarily analyzed the data. We thank Ms. Jamie Wallace, BA, for data analysis and coordination, and Ms. Caitlin Lupton, MSc, for research assistance and administrative support. The statements in this publication are solely the responsibility of the authors and do not necessarily represent the views of the National Cancer Institute and its Board of Governors.

Author contributions

Drs. Lu and Zhang had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design all authors. Acquisition of data Wharam. Analysis and interpretation of the data all authors. Drafting of the manuscript Lu, Callahan. Critical revision of the manuscript for important intellectual content all authors. Statistical analysis Zhang, Xu. Obtained funding Wharam, Lu. Administrative, technical, or material support Wharam, Callahan, Zhang. Study supervision Wharam, Lu.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest or financial disclosures to report.

Supplementary material

10549_2018_4821_MOESM1_ESM.docx (32 kb)
Supplementary material 1 (DOCX 32 KB)

References

  1. 1.
    American Cancer Society (2016) Breast cancer facts and figs. 2015–2016. American Cancer Society, Inc., AtlantaGoogle Scholar
  2. 2.
    Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, McDonald C, Muir BB, Prescott RJ, Shepherd SM et al (1994) The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. Br J Cancer 70(3):542–548CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfusson B (1988) Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 297(6654):943–948CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Cancer Intervention Surveillance Modeling Network (CISNET) Collaborators (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784–1792.  https://doi.org/10.1056/NEJMoa050518 CrossRefPubMedGoogle Scholar
  5. 5.
    Cronin KA, Feuer EJ, Clarke LD, Plevritis SK (2006) Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst Monogr.  https://doi.org/10.1093/jncimonographs/lgj015 CrossRefPubMedGoogle Scholar
  6. 6.
    Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125(1):191–200.  https://doi.org/10.1007/s10549-010-0952-6 CrossRefPubMedGoogle Scholar
  7. 7.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352.  https://doi.org/10.1016/S0140-6736(15)61074-1 CrossRefGoogle Scholar
  8. 8.
    Claxton G, Rae M, Long M, Damico A, Foster G, Whitmore H (2017) The Kaiser Family Foundation and Health Research and Educational Trust employer benefits 2017 annual survey. The Kaiser Family Foundation, Menlo ParkGoogle Scholar
  9. 9.
    Wharam JF, Zhang F, Lu CY, Wagner AK, Nekhlyudov L, Earle CC, Soumerai SB, Ross-Degnan D (2018) Breast cancer diagnosis and treatment after high-deductible insurance enrollment. J Clin Oncol 36(11):1121–1127.  https://doi.org/10.1200/JCO.2017.75.2501 CrossRefPubMedGoogle Scholar
  10. 10.
    Wu XC, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, Fleming ST, Morris CR, Huang B, Trentham-Dietz A, Lipscomb J (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30(2):142–150.  https://doi.org/10.1200/JCO.2011.36.8399 CrossRefPubMedGoogle Scholar
  11. 11.
    Livaudais JC, Hershman DL, Habel L, Kushi L, Gomez SL, Li CI, Neugut AI, Fehrenbacher L, Thompson B, Coronado GD (2012) Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat 131(2):607–617.  https://doi.org/10.1007/s10549-011-1762-1 CrossRefPubMedGoogle Scholar
  12. 12.
    Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL (2011) The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 117(1):180–189.  https://doi.org/10.1002/cncr.25542 CrossRefPubMedGoogle Scholar
  13. 13.
    Wharam JF, Zhang F, Landon BE, LeCates R, Soumerai S, Ross-Degnan D (2016) Colorectal cancer screening in a nationwide high-deductible health plan before and after the Affordable Care Act. Med Care 54(5):466–473.  https://doi.org/10.1097/MLR.0000000000000521 CrossRefPubMedGoogle Scholar
  14. 14.
    Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL (2004) An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 39(6 Pt 1):1733–1749.  https://doi.org/10.1111/j.1475-6773.2004.00315.x CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lu CY, Adams AS, Ross-Degnan D, Zhang F, Zhang Y, Salzman C, Soumerai SB (2011) Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorder. Psychiatr Serv 62(2):186–193.  https://doi.org/10.1176/ps.62.2.pss6202_0186 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    United States Bureau of the Census (1994) Geographical areas reference manual. United States Bureau of the Census, Washington, DCGoogle Scholar
  17. 17.
    Krieger N (1992) Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 82(5):703–710CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV (2003) Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures—the public health disparities geocoding project. Am J Public Health 93(10):1655–1671CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Trivedi AN, Zaslavsky AM, Schneider EC, Ayanian JZ (2006) Relationship between quality of care and racial disparities in Medicare health plans. JAMA 296(16):1998–2004CrossRefPubMedGoogle Scholar
  20. 20.
    Trivedi AN, Rakowski W, Ayanian JZ (2008) Effect of cost sharing on screening mammography in medicare health plans. N Engl J Med 358(4):375–383.  https://doi.org/10.1056/NEJMsa070929 CrossRefPubMedGoogle Scholar
  21. 21.
    Selby JV, Fireman BH, Swain BE (1996) Effect of a copayment on use of the emergency department in a health maintenance organization. N Engl J Med 334(10):635–641CrossRefPubMedGoogle Scholar
  22. 22.
    Ethnic Technologies (2018) Ethnic Technologies: the leader in multicultural marketing. http://www.ethnictechnologies.com/. Accessed 27 April 2018
  23. 23.
    Fiscella K, Fremont AM (2006) Use of geocoding and surname analysis to estimate race and ethnicity. Health Serv Res 41(4 Pt 1):1482–1500PubMedPubMedCentralGoogle Scholar
  24. 24.
    Yang D, Dalton JE (2012) A unified approach to measuring the effect size between two groups using SAS®. In: SAS Global Forum 2012—statistics and data analysis, Orlando, FLGoogle Scholar
  25. 25.
    Lambert D (1992) Zero-inflated Poisson regression, with an application to defects in manufacturing. Technometrics 34(1):1–14CrossRefGoogle Scholar
  26. 26.
    Hall D (2000) Zero-inflated Poisson and binomial regression with random effects: a case study. Biometrics 56(4):1030–1039CrossRefPubMedGoogle Scholar
  27. 27.
    Hershman DL, Tsui J, Meyer J, Glied S, Hillyer GC, Wright JD, Neugut AI (2014) The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/dju319 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, Magai C, Tsai WY, Jacobson JS, Hershman DL (2012) Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. J Clin Oncol 30(31):3800–3809.  https://doi.org/10.1200/JCO.2012.43.8168 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wharam JF, Zhang F, Eggleston EM, Lu CY, Soumerai S, Ross-Degnan D (2017) Diabetes outpatient care and acute complications before and after high-deductible insurance enrollment: a natural experiment for translation in diabetes (NEXT-D) study. JAMA Intern Med 177(3):358–368.  https://doi.org/10.1001/jamainternmed.2016.8411 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wharam JF, Graves AJ, Zhang F, Soumerai SB, Ross-Degnan D, Landon BE (2012) Two-year trends in cancer screening among low socioeconomic status women in an HMO-based high-deductible health plan. J Gen Intern Med 27(9):1112–1119.  https://doi.org/10.1007/s11606-012-2057-x CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Reiss SK, Ross-Degnan D, Zhang F, Soumerai SB, Zaslavsky AM, Wharam JF (2011) Effect of switching to a high-deductible health plan on use of chronic medications. Health Serv Res 46(5):1382–1401.  https://doi.org/10.1111/j.1475-6773.2011.01252.x CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wharam JF, Graves AJ, Landon BE, Zhang F, Soumerai SB, Ross-Degnan D (2011) Two-year trends in colorectal cancer screening after switch to a high-deductible health plan. Med Care 49(9):865–871.  https://doi.org/10.1097/MLR.0b013e31821b35d8 CrossRefPubMedGoogle Scholar
  33. 33.
    Wharam JF, Galbraith AA, Kleinman KP, Soumerai SB, Ross-Degnan D, Landon BE (2008) Cancer screening before and after switching to a high-deductible health plan. Ann Intern Med 148(9):647–655CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Christine Y. Lu
    • 1
  • Fang Zhang
    • 1
  • Anita K. Wagner
    • 1
  • Larissa Nekhlyudov
    • 2
  • Craig C. Earle
    • 3
  • Matthew Callahan
    • 1
  • Robert LeCates
    • 1
  • Xin Xu
    • 1
  • Dennis Ross-Degnan
    • 1
  • J. Frank Wharam
    • 1
  1. 1.Division of Health Policy and Insurance Research, Department of Population MedicineHarvard Medical School and Harvard Pilgrim Health Care InstituteBostonUSA
  2. 2.Department of MedicineBrigham & Women’s HospitalBostonUSA
  3. 3.Ontario Institute for Cancer ResearchTorontoCanada

Personalised recommendations